⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 18, 2024EClinicalMedicineOpen Access

Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial

Amparo L. Figueroa Kashif Ali Gary Berman Haiyu Zhou Weiping Deng W. Xu Stephanie Lussier Bethany Girard Frank J. Dutko Karen Slobod Anne Yeakey Frances Priddy Jacqueline M. Miller Rituparna Das

View Full Paper

Ask AI

Bookmark

Share

Abstract

Longitudinal changes in vaccination-induced immune response remain inadequately characterized in adolescents. We present long-term safety, immunogenicity, and COVID-19 incidence following a 2-dose mRNA-1273 100-μg primary series, and immunogenicity following a single dose of mRNA-1273 50 μg in vaccine-naïve adolescents.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Figueroa et al. (2024) studied this question.

synapsesocial.com/papers/68e5fda8b6db6435875910fc https://doi.org/10.1016/j.eclinm.2024.102720

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescentscohort · 2025 · 4 citations
2A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccineRCT · 2021 · 225 citations
3Safety and Immunogenicity of an mRNA-1273 Booster in Children2024 · 10 citations
4Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases2024 · 37 citations
5Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineClinical Trial · 2020 · 10,088 citations